Literature DB >> 30351348

Mycoplasma genitalium Infections in Women Attending a Sexually Transmitted Disease Clinic in New Orleans.

Rebecca A Lillis1, David H Martin1,2, M Jacques Nsuami1.   

Abstract

BACKGROUND: Mycoplasma genitalium has been significantly and nonsignificantly associated with cervicitis, urethritis, or vaginal discharge. This study examined the associations of M. genitalium with selected sexually transmitted infections (STIs) and demographic, behavioral, and clinical factors among women attending a sexually transmitted disease (STD) clinic in New Orleans.
METHODS: Women aged ≥18 years who presented to the New Orleans STD clinic provided sociodemographic data and sexual behavior; STI, obstetric, and gynecologic history; and urine, vaginal, endocervical, and rectal specimens. Specimens were tested for M. genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma hominis, Ureaplasma species, and yeast. Bacterial vaginosis (BV) was diagnosed by Nugent score, and cervicitis was defined as ≥30 polymorphonuclear leukocytes per high-power microscopic field on a cervical Gram stain or yellow mucopus on an endocervical swab.
RESULTS: Among 400 women studied, M. genitalium was independently significantly associated with age <25 years (P < .03) and with ≥2 sexual partners in the last 12 months (P < .003). Neisseria gonorrhoeae (adjusted odds ratio [AOR], 1.75; P = .103), C. trachomatis (AOR, 1.43; P = .247), and T. vaginalis (AOR, 1.60; P = .120) independently increased the odds of infection with M. genitalium. Controlling for other STIs and BV, there was a positive trend for M. genitalium to predict cervicitis (AOR, 3.18 [95% confidence interval, .99-10.2]; P = .05).
CONCLUSIONS: Mycoplasma genitalium in our study displayed the clinical features of C. trachomatis and N. gonorrhoeae, the 2 organisms that drive research agendas in diagnosis, treatment, and prevention of bacterial STIs.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  clinical epidemiology; emerging pathogens; infectious diseases

Mesh:

Year:  2019        PMID: 30351348     DOI: 10.1093/cid/ciy922

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Evaluation of molecular testing for Mycoplasma genitalium for symptomatic women.

Authors:  Carina Brehony; Maeve Eogan; John S Lambert; Richard J Drew
Journal:  Ir J Med Sci       Date:  2021-09-21       Impact factor: 2.089

2.  Cervicitis: Balancing the Goals of Empiric Therapy and Antimicrobial Stewardship to Improve Women's Health.

Authors:  Jodie Dionne-Odom; Jeanne Marrazzo
Journal:  Sex Transm Dis       Date:  2020-06       Impact factor: 2.830

3.  Characteristics of Mycoplasma genitalium Urogenital Infections in a Diverse Patient Sample from the United States: Results from the Aptima Mycoplasma genitalium Evaluation Study (AMES).

Authors:  Lisa E Manhart; Charlotte A Gaydos; Stephanie N Taylor; Rebecca A Lillis; Edward W Hook; Jeffrey D Klausner; Carmelle V Remillard; Melissa Love; Byron McKinney; Damon K Getman
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

Review 4.  Sexually transmitted infections in pregnant women from sub-Saharan Africa.

Authors:  Bongekile Ngobese; Nathlee S Abbai
Journal:  S Afr J Infect Dis       Date:  2021-12-09

5.  Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches.

Authors:  Lisa E Manhart; William M Geisler; Catriona S Bradshaw; Jørgen S Jensen; David H Martin
Journal:  Emerg Infect Dis       Date:  2022-08       Impact factor: 16.126

6.  Rectal Mycoplasma genitalium in Patients Attending Sexually Transmitted Disease Clinics in China: An Infection That Cannot Be Ignored.

Authors:  Yan Han; Yue-Ping Yin; Jing-Wei Liu; Kai Chen; Bang-Yong Zhu; Ke Zhou; Mei-Qin Shi; Wen-Qi Xu; Tulip A Jhaveri; Xiang-Sheng Chen
Journal:  Infect Drug Resist       Date:  2021-06-30       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.